{
    "clinical_study": {
        "@rank": "144835", 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      Evaluate the safety and feasibility of administering recombinant adenovirus containing the\n      ornithine transcarbamylase gene to adults with partial ornithine transcarbamylase\n      deficiency."
        }, 
        "brief_title": "Phase I Pilot Study of Liver-Directed Gene Therapy for Partial Ornithine Transcarbamylase Deficiency", 
        "condition": "Ornithine Transcarbamylase Deficiency Disease", 
        "condition_browse": {
            "mesh_term": [
                "Deficiency Diseases", 
                "Ornithine Carbamoyltransferase Deficiency Disease"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This a dose escalation study to estimate the maximum tolerated dose of\n      recombinant adenovirus encoded with the ornithine transcarbamylase gene.\n\n      Patients receive a single dose of virus infused into the liver under fluoroscopic guidance.\n      Groups of 3 patients receive successively higher doses of virus; each cohort is observed for\n      safety for 3 weeks before entry of the next group.\n\n      Patients are followed weekly for 1 month, then every 3 months until stable."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics-- Confirmed partial ornithine transcarbamylase deficiency\n        Asymptomatic, i.e., at least 1 month since hyperammonemia --Prior/Concurrent Therapy-- Not\n        specified --Patient Characteristics-- No pregnant or nursing women Negative pregnancy test\n        required of fertile women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "October 18, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004386", 
            "org_study_id": "199/12054", 
            "secondary_id": "CSH-3660"
        }, 
        "intervention": {
            "intervention_name": "recombinant adenovirus containing the ornithine transcarbamylase gene", 
            "intervention_type": "Genetic"
        }, 
        "keyword": [
            "inborn errors of metabolism", 
            "rare disease", 
            "urea cycle disorder"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "Children's Research Institute", 
            "last_name": "Mark Batshaw", 
            "role": "Study Chair"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004386"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "collaborator": {
                "agency": "Children's Research Institute", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "October 1995", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2000"
    }, 
    "geocoordinates": {}
}